{"preliminary_commentary":{"by_channel":{"x_thread":10,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06638541\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"DESTINATION 2","nct_id":"NCT06638541","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destination-2-nct06638541. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DESTINATION 2","arms":[{"description":"Arm 1 (Uniform dose) will receive 27 Gy in 2 fractions to the whole prostate + seminal vesicles (SV), the CTV, with 0 mm CTV-PTV margin.","label":"Uniform dose","type":"ACTIVE_COMPARATOR"},{"description":"Arm 2 (De-escalated dose) will use two dose levels:\n\nThe benign prostate (on MRI) will receive 20 Gy in 2 fractions with a 0mm PTV margin.\n\nThe intraprostatic tumour mass(es) as seen on MRI will receive 27 Gy in 2 fractions. A 4mm GTV-PTV margin will be added to the MR visible tumour to form PTV 27Gy.","label":"De-escalated dose","type":"EXPERIMENTAL"}],"collaborators":["Elekta Limited","MRL Consortium"],"completion_date":{"date":"2027-01-01","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":54,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Prostate radical radiotherapy","otherNames":[],"type":"RADIATION"}],"last_update":"2026-03-23","lead_sponsor":"Royal Marsden NHS Foundation Trust","official_title":"Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions - a Randomised Trial","overall_status":"RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2027-01-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Acute GU toxicity","timeFrame":"12 weeks"}],"references":[{"citation":"Cooper S, Alexander S, Breitkreutz D, Casey F, Christodouleas J, Dassen MG, Dell'acqua V, Dunlop A, Herbert T, Kolias P, Mitchell A, Pos FJ, Westley R, Tree AC, Van Der Heide UA, Vesprini D. Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial. BMJ Open. 2026 May 7;16(5):e111791. doi: 10.1136/bmjopen-2025-111791.","pmid":"42097645","type":"DERIVED"}],"start_date":{"date":"2025-01-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions","url":"https://clinicaltrials.gov/study/NCT06638541"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destination-2-nct06638541"}